CERo Therapeutics Holdings, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CERO research report →
Companywww.cero.bio
CERo Therapeutics Holdings, Inc. , an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors.
- CEO
- Christopher Ehrlich
- IPO
- 2021
- Employees
- 8
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $23.84K
- P/E
- -0.03
- P/S
- 0.00
- P/B
- -0.06
- EV/EBITDA
- 0.01
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 396.51%
- ROIC
- 211.98%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-19,920,262 · -157.63%
- EPS
- $-22.58 · -228.68%
- Op Income
- $-18,463,149
- FCF YoY
- -177.73%
Performance & Tape
- 52W High
- $26.99
- 52W Low
- $0.02
- 50D MA
- $0.03
- 200D MA
- $1.78
- Beta
- 0.24
- Avg Volume
- 574.73K
Get TickerSpark's AI analysis on CERO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 4, 26 | Francois Eric | other | 1,823,278 |
| Feb 13, 26 | Francois Eric | other | 0 |
| Jan 7, 26 | Rolfe Lindsey | other | 690,900 |
| Jan 7, 26 | LAPORTE KATHLEEN | other | 690,900 |
| Jan 7, 26 | Pierce Kristen | other | 1,612,099 |
| Jan 7, 26 | Patel Shami | other | 690,900 |
| Jan 7, 26 | ATWOOD BRIAN G | other | 1,612,099 |
| Jan 7, 26 | Ehrlich Christopher B | other | 4,530,997 |
| Jan 7, 26 | Byrnes Michael | other | 690,900 |
| Jan 7, 26 | KUCHARCHUK ANDREW ALBERT | other | 1,162,099 |
Our CERO Coverage
We haven't published any research on CERO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CERO Report →